Table 1 Weight-loss drugs in clinical development after 2015

From: Signaling pathways in obesity: mechanisms and therapeutic interventions

Agent type	Agent	Indication	Manufacturer	Trials	ClinicalTrials.gov ID/ref.
Energy intake
MC4R agonist	PL-8905	Obesity	Palatin Technologies	Announced	Not Recorded
NPY5R antagonist	S-237648	Obesity	Shionogi & Co.	In-house	See R&D Pipeline
Triple reuptake inhibitor/SNDRI	Tesofensine/NS-2330	Obesity	NeuroSearch A/S	Phase 2	NCT00394667
Peripheral CB1 receptor blocker	GFB-024 (inverse agonist)	Kidney diseases	Goldfinch Bio	Phase 1	NCT04880291
	AM-6545 (antagonist)	Obesity	MAKScientific	Preclinical	See R&D Pipeline
GLP-1R agonist	Beinaglutide/Benaglutide	Obesity	Shanghai Benemae	Phase 3	NCT03986008
	Dulaglutide	T2D	Eli Lilly and Company	Phase 3	NCT03015220
				Phase 2	NCT02973100
				Phase 4	NCT02750410
	LY3502970	Obesity, T2D	Eli Lilly and Company	Phase 1	NCT05086445
				Phase 2	NCT05051579
				Phase 2	NCT05048719
	Efpeglenatide/^LAPSExd4 Analog	T2D	Hanmi Pharmaceutical	Phase 3	NCT03353350
	Exenatide	HO	AstraZeneca	Phase 3	NCT02860923
	PB-119	T2D	PegBio Co.	Phase 3	NCT04504396
				Phase 3	NCT04504370
	Danuglipron/PF-06882961	Obesity, T2D	Pfizer	Phase 2	NCT04707313
				Phase 2	NCT04617275
				Phase 2	NCT03985293
	PF-07081532	Obesity, T2D	Pfizer	Phase 1	NCT04305587
	RGT001-075	T2D	Regor Therapeutics	Phase 2	NCT05297045
	Noiiglutide/SHR20004	Obesity	Hansoh Pharma	Phase 2	NCT04799327
	TG103	Obesity	CSPC Pharmaceutical	Phase 2	NCT05299697
	TTP273	T2D	vTv Therapeutics	Phase 2	NCT02653599
	XW003	Obesity	Sciwind Biosciences	Phase 2	NCT05111912
	XW004	Obesity, T2D	Sciwind Biosciences	Phase 1	NCT05184322
GCGR agonist	HM15136/^LAPSGlucagon Analog	Obesity, T2D	Hanmi Pharmaceutical	Phase 1	NCT04167553
	NN9030/NNC9204-0530	Obesity	Novo Nordisk	Phase 1	NCT02835235
GIPR agonist	ZP 6590	Obesity	Zealand Pharma	Preclinical	See R&D Pipeline
GLP-1R/GCGR dual agonist	Pemvidutide/ALT-801	Obesity	Altimmune	Phase 2	NCT05295875
	BI 456906	Obesity	Boehringer Ingelheim	Phase 2	NCT04667377
	CT-388	T2D	Carmot Therapeutics	Phase 1	NCT04838405
	CT-868	Obesity, T2D	Carmot Therapeutics	Phase 2	NCT05110846
	DD01	Obesity, T2D	D&D Pharmatech	Phase 1	NCT04812262
	JNJ-64565111	Obesity, T2D	Johnson & Johnson	Phase 2	NCT03586830
				Phase 2	NCT03486392
	NN9277/NNC9204-1177	Obesity	Novo Nordisk	Phase 1	NCT02941042
	Efinopegdutide/^LAPSGLP/GCG	NASH	Hanmi Pharmaceutical	Phase 2	NCT03486392
	SAR425899	T2D	Sanofi	Phase 1	NCT03376802
	OXM analog—Cotadutide/MEDI0382	T2D	AstraZeneca	Phase 1	NCT02548585
				Phase 1	NCT04208620
	OXM analog—G3215	Obesity, T2D	Imperial College London	Phase 1	NCT02692040
	OXM analog—IBI362/LY3305677	Obesity, T2D	Eli Lilly and Company	Phase 2	NCT04904913
				Phase 1	NCT04440345
	OXM analog—MOD-6031	Obesity, T2D	OPKO Health	Phase 1	NCT02692781
	OXM analog—OPK-88003/LY2944876	Obesity, T2D	OPKO Health	Phase 2	NCT03406377
GLP-1R/GIPR dual agonist	HS-20094	T2D	Hansoh Pharma	Phase 1	NCT05116410
	Tirzepatide/LY3298176	Obesity, T2D	Eli Lilly and Company	Phase 3	NCT05024032
				Phase 3	NCT04844918
				Phase 3	NCT04657016
				Phase 3	NCT04660643
				Phase 3	NCT04657003
				Phase 3	NCT04184622
GLP-1R/GIPR/GCGR triple agonist	HM15211/^LAPSTriple Agonist	NASH	Hanmi Pharmaceutical	Phase 2	NCT04505436
	LY3437943	Obesity, T2D	Eli Lilly and Company	Phase 1	NCT04823208
				Phase 2	NCT04881760
				Phase 2	NCT04867785
	NN9423/NNC9204-1706	Obesity	Novo Nordisk	Phase 1	NCT03095807
	NNC0480-0389
	SAR441255	Obesity	Sanofi	Phase 1	NCT04521738
GLP-1R agonist and GIPR antagonist	AMG133	Obesity	Amgen	Phase 1	NCT04478708
	GMA106	Obesity	Gmax Biopharm	Phase 1	NCT05054530
DPP-4 inhibitor	HSK7653	T2D	Haisco Pharmaceutical	Phase 3	NCT04556851
	Sitagliptin	T2D, NAFLD	Merck & Co.	Phase 4	NCT05195944
				Phase 3	NCT02849080
	Yogliptin	Obesity, T2D	Easton Biopharmaceuticals	Phase 3	NCT05318326
AMYR agonist	Cagrilintide/NN9838/AM833/NNC0174-0833	Obesity, T2D	Novo Nordisk	Phase 1	NCT04940078
				Phase 1	NCT05254158
				Phase 2	NCT03856047
	ZP8396	Obesity	Zealand Pharma	Phase 1	NCT05096598
AMYR/CTR dual agonist	KBP-042	T2D	Nordic Bioscience	Phase 2	NCT03230786
	KBP-089	T2D	Nordic Bioscience	Phase 1	NCT03907202
TAS2R agonist	ARD-101	Obesity	Aardvark Therapeutics	Phase 2	NCT05121441
PYY/Y2R signaling	NNC0165-1562	Obesity	Novo Nordisk	Phase 1	NCT03574584
	PYY1875/NNC0165-1875	Obesity	Novo Nordisk	Phase 1	NCT03707990
	NN9748/NN9747	Obesity, T2D	Novo Nordisk	Phase 1	NCT03574584
Ghrelin signaling	NOX-B11	Obesity	NOXXON Pharma	Preclinical	Not Recorded
	GLWL-01	PWS	GLWL Research	Phase 2	NCT03274856
	RM-853/T-3525770	PWS	Rhythm Pharmaceuticals	Preclinical	See R&D Pipeline
	TZP-301	Obesity	Ocera Therapeutics	Preclinical	Not Recorded
	EX-1350	Obesity, T2D	Elixir Pharmaceuticals	Preclinical	Not Recorded
Leptin analog	Metreleptin	Lipodystrophy	AstraZeneca	Phase 3	NCT05164341
Leptin sensitizer	Celastrol	Obesity, T2D	Research Use Only	Preclinical	PMID: 26000480⁴²⁰
	Withaferin A	Obesity, T2D	Research Use Only	Phase 1	PMID: 30904387⁴²¹
	ERX1000	Obesity	ERX Pharmaceuticals	Phase 1	NCT04890873
GDF15 agonist	LA-GDF15	Obesity	Novo Nordisk	Phase 1	See R&D Pipeline
	LY3463251	Obesity	Eli Lilly and Company	Phase 1	NCT03764774
α7-nAChR agonist	GTS-21/DMXB-A	Obesity	Otsuka Pharmaceutical	Phase 1	NCT02458313
Energy absorption
Strain product	WST01	Obesity, T2D	SJTUSM	Phase 2	NCT04797442
	Xla1	Obesity	YSOPIA Bioscience	Phase 1	NCT04663139
Orlistat and acarbose	EMP16-02	Obesity	Empros Pharma AB	Phase 1	NCT04521751
Energy storage
MGAT2 inhibitor	BMS-963272	Obesity	Bristol Myers Squibb	Phase 1	NCT04116632
	S-309309	Obesity	Shionogi & Co.	In-house	See R&D Pipeline
DGAT2 inhibitor	Ervogastat/PF-06865571	NASH, NAFLD	Pfizer	Phase 1	NCT03513588
Sirt1/AMPK/eNOS signaling	NS-0200/Leucine-Metformin-Sildenafil	Obesity	NuSirt Biopharma	Phase 2	NCT03364335
Labisia pumila extract	SKF7	Obesity	Medika Natura	Phase 2	NCT04557267
Stimulating IDE synthesis	Cyclo-Z (cyclo(his-pro) plus zinc)	T2D	NovMetaPharma	Phase 2	NCT03560271
					NCT02784275
αGI inhibitor	Sugardown/BTI320	Prediabetes	Boston Therapeutics	Phase 2	NCT02358668
CCR2/CCR5 dual agonist	Cenicriviroc	T2D, NAFLD	AbbVie	Phase 2	NCT02330549
Energy expenditure
SGLT2 inhibitor	Ipragliflozin/ASP1941	T2D	Astellas Pharma	Phase 3	NCT02452632
	Bexagliflozin/EGT1442	T2D	Theracos	Phase 3	NCT02836873
				Phase 3	NCT02715258
				Phase 3	NCT02558296
	Remogliflozin etabonate	T2D	Avolynt	Phase 2	NCT02537470
	Canagliflozin	Obesity, T2D	Johnson & Johnson	Phase 4	NCT02360774
	Dapagliflozin	T2D, HF, CKD	AstraZeneca	Phase 2	NCT05179668
				Phase 4	NCT04249778
				Phase 2	NCT03968224
				Phase 3	NCT02413398
	Empagliflozin	T1D, T2D	Boehringer Ingelheim	Phase 3	NCT04233801
				Phase 2	NCT03132181
				Phase 4	NCT03157414
				Phase 3	NCT02863328
				Phase 3	NCT02580591
				Phase 3	NCT02414958
	Ertugliflozin	T2D, HF	Merck & Co.	Phase 3	NCT03717194
SGLT1/2 inhibitor	Licogliflozin/LIK066	Obesity	Novartis	Phase 2	NCT03320941
				Phase 2	NCT03100058
	Sotagliflozin	T1D, T2D, CKD	Lexicon Pharmaceuticals	Phase 3	NCT03242252
				Phase 3	NCT03242018
				Phase 3	NCT02531035
				Phase 3	NCT02384941
MetAP2 inhibitor	Beloranib/ZGN-440/ZGN-433	Obesity	Larimar Therapeutics	Phase 2	NCT01666691
	ZGN-1061	Obesity, T2D	Larimar Therapeutics	Phase 2	NCT03254368
FGF21/FGFR1c/β-Klotho signaling	LLF580	Obesity	Novartis Pharmaceuticals	Phase 1	NCT03466203
	NN9499/NNC0194-0499	Obesity	Novo Nordisk	Phase 1	NCT03479892
	MK-3655/NGM313	Obesity, NASH	Merck & Co.	Phase 1	NCT02708576
					NCT04583423
	BFKB8488A	NAFLD	Genentech	Phase 1	NCT02593331
FGFR4 inhibitor	IONIS-FGFR4Rx	Obesity	Ionis Pharmaceuticals	Phase 2	NCT02476019
FXR agonist	ASC42	Obesity, NASH	Gannex Pharma	Phase 1	See R&D Pipeline
THR-β agonist	ASC41	Obesity, NAFLD	Gannex Pharma	Phase 1	NCT04686994
sGC stimulator	Praliciguat/IW-1973	T2D	Cyclerion Therapeutics	Phase 2	NCT02906579
Neutrophil elastase inhibitor	PHP-303	Obesity	pH Pharma	Phase 1	NCT03775278
PDE4/5 inhibitor	Roflumilast	Obesity	Altana Pharma	Phase 3	NCT04800172
	Tadalafil	Obesity	Eli Lilly and Company	Phase 2	NCT02819440
Glabridin analog	HSG4112	Obesity	Glaceum	Phase 1	NCT05310032
				Phase 2	NCT05197556
				Phase 1	NCT04703764
ActRII inhibition	Bimagrumab/BYM338	T2D	Novartis	Phase 2	NCT03005288

MC4R melanocortin-4 receptor, NPY5R neuropeptide y receptor y5, R&D research and development, SNDRI serotonin–norepinephrine–dopamine reuptake inhibitor, CB1 cannabinoid receptor 1, GLP-1R glucagon-like peptide 1 receptor, T2D type 2 diabetes, LAPS long-acting peptide/protein discovery, HO hypothalamic obesity, GCGR glucagon receptor, GIPR glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide receptor, NASH nonalcoholic steatohepatitis, OXM oxyntomodulin, DPP-4 dipeptidyl peptidase-4, NAFLD nonalcoholic fatty liver disease, AMYR amylin receptor, CTR calcitonin receptor, TAS2R bitter taste receptor class 2, PYY peptide tyrosine-tyrosine, Y2R neuropeptide y receptor type 2, PWS Prader–Willi syndrome, GDF15 growth differentiation factor 15, α7-nAChR alpha7 nicotinic acetylcholine receptor, MGAT2 monoacylglycerol acyltransferase 2, DGAT2 diacylglycerol acyltransferase 2, IDE insulin degrading enzyme, αGI alpha-glucosidase inhibitor, CCR2/5 C-C chemokine receptor type 2/5, SGLT1/2 sodium-glucose cotransporter 1/2, HF heart failure, CKD chronic kidney disease, T1D type 1 diabetes, MetAP2 methionine aminopeptidase 2, FGF21 fibroblast growth factor 21, FGFR1c fibroblast growth factor receptor 1c isoform, FGFR4 fibroblast growth factor receptor 4, FXR farnesoid x receptor, THR-β thyroid hormone receptor beta, sGC soluble guanylate cyclase, PDE4/5 phosphodiesterase-4/5, ActRII activin type II receptors
Zealand Pharma R&D Pipeline: https://www.zealandpharma.com/product-pipeline
Rhythm Pharmaceuticals R&D Pipeline: https://www.rhythmtx.com/our-pipeline-old
Shionogi & Co. R&D Pipeline: https://www.shionogi.com/global/en/innovation/pipeline.html
MAKScientific R&D Pipeline: https://makscientific.com/drug_pipeline.html
Gannex Pharma R&D Pipeline: https://www.gannexpharma.com/portal/list/index/id/9.html
Novo Nordisk R&D Pipeline: https://www.novonordisk.com/science-and-technology/r-d-pipeline.html

Back to article page

Search

Quick links